Background {#Sec1}
==========

*Corynebacterium pseudotuberculosis* biovar *ovis* is a Gram-positive facultative intracellular pathogen. It is the etiologic agent of Caseous Lymphadenitis (CLA) in small ruminants, a disease characterized by abscess formation in lymph nodes and internal organs \[[@CR1]\]. Cases of human infection caused by *C. pseudotuberculosis* have been reported and are associated with occupational exposure \[[@CR1]\]. CLA is globally distributed and causes significant economic losses in goats, and sheep herds \[[@CR2]\]. The pathogenic process of *C. pseudotuberculosis* in the host comprises two phases: (i) initial colonization and replication in lymph nodes that drain the site of infection, which is associated with pyogranuloma formation, and (ii) a secondary cycle of replication and dissemination via the lymphatic or circulatory systems. This dissemination is promoted by the action of phospholipase D (PLD) exotoxin, the major virulence factor of *C. pseudotuberculosis,* which allows this pathogen to contaminate visceral organs and lymph nodes, where it ultimately induces lesion formation \[[@CR3]--[@CR5]\].

Exported proteins reportedly favor the infection process in pathogenic bacteria; this class of proteins is involved in adhesion and invasion of host cells, nutrient acquisition, toxicity, and in the evasion of the host immune system \[[@CR6]\]. Different strategies like the transposon mutagenesis have been adopted to identify *C. pseudotuberculosis* biovar *ovis* exported proteins \[[@CR7]\]. Additionally, comparative proteomics has been applied to characterize the extracellular proteome of *C. pseudotuberculosis* biovar *ovis,* as well as, the extracellular immunoproteome (strains C231\_*ovis* and 1002\_*ovis*) \[[@CR8]--[@CR11]\]. In these studies, some proteins of the strain 1002*\_ovis*, suspected to be virulence factors, were not detected suggesting this strain presents a low virulence. The surface proteome of *C. pseudotuberculosis* biovar *ovis* was also characterized using bacterial strains isolated from the lymph nodes of naturally infected sheep. This proteomic analysis allowed the identification of proteins that could favor the survival of this pathogen during the chronic phase of CLA \[[@CR12]\].

The experimental passage of bacterial pathogens through in vitro or in an in vivo model is a strategy that has been applied to evaluate the virulence potential of several pathogens. By generating a confrontation between the pathogen and the dynamic network of host factors, including the immune system components, it helps to identify bacterial factors involved in virulence \[[@CR12]--[@CR19]\]. In this study, the strain 1002*\_ovis* was experimentally inoculated in mice \[[@CR20], [@CR21]\] to identify factors which could contribute to virulence in *C. pseudotuberculosis* biovar *ovis.* Comparative proteomics of the culture supernatant from this strain collected before and after the experimental passage in mice was carried out to identify factors that might contribute to virulence of 1002\_*ovis*.

Methods {#Sec2}
=======

Bacterial strains and growth conditions {#Sec3}
---------------------------------------

The *C. pseudotuberculosis* biovar *ovis* strain 1002 (1002\_*ovis*) was isolated from a goat in Brazil; this strain was cultivated under standard conditions in brain--heart infusion broth (BHI-HiMedia Laboratories Pvt. Ltd., India) at 37 °C. When necessary, 1.5% of agar was added to the medium for a solid culture. For extracellular proteomic analyses, 1002*\_ovis* was grown in a chemically defined medium (CDM) \[(Na~2~HPO~4~\_7H~2~O (12.93 g/L), KH~2~PO4 (2.55 g/L), NH~4~Cl (1 g/L), MgSO~4~\_7H~2~O (0.20 g/L), CaCl~2~ (0.02 g/L) and 0.05% (v/v) Tween 80\], 4% (v/v) MEM Vitamins Solution (Invitrogen, Gaithersburg, MD, USA), 1% (v/v) MEM Amino Acids Solution (Invitrogen), 1% (v/v) MEM Non-Essential Amino Acids Solution (Invitrogen), and 1.2% (w/v) glucose at 37 °C \[[@CR22]\].

Experimental infection of strain 1002\_*ovis* in a murine model (in vivo assay) {#Sec4}
-------------------------------------------------------------------------------

The standardization of the parameters for infection was performed according to Moraes et al. \[[@CR20]\] and Ribeiro et al. \[[@CR21]\]. Female BALB/c mice between six and eight weeks old were used in all experiments. They were provided by the Animal Care Facility of the Biological Sciences Institute from the Federal University of Minas Gerais and were handled by the guidelines of the UFMG Ethics Committee on Animal Testing (Permit Number: CETEA 103/2011). For the bacterial passage assay using the murine model, two groups of three mice each was infected via intraperitoneal injection with 10^6^ colony forming units (CFU) of strain 1002\_*ovis*. Thirty-six hours after infection, all animals were sacrificed. Their spleens were aseptically removed to recover the bacterial strain, as described below: the spleen removed from each animal was then, individually macerated in sterile saline solution (0.9% NaCl~2~), seeded onto BHI agar plates and incubated for 48 h at 37 °C. Subsequently, one recovered bacterial colony was cultured in BHI broth. The recovered bacteria were then referred to as Recovered (Rc). For the bacterial virulence assay, we used the freshly recovered bacteria and bacteria that did not contact the murine host as a control, which is referred to as Control (Ct). Groups of five mice were infected with Rc and Ct, via intraperitoneal injection of a suspension containing 10^6^ CFU or 10^5^ CFU. The animals' survival rates were calculated and represented in GraphPad Prism v.5.0 (GraphPad Software, San Diego, CA, USA) using the Kaplan-Meier survival function. The results of 1002\_*ovis* CFU count in the organs were calculated using the two-way ANOVA test.

Preparation of proteins from culture filtrates for proteome analysis {#Sec5}
--------------------------------------------------------------------

For proteomic analysis, the Ct and Rc (three independently recovered colonies) that was obtained from infected mice spleens as described above were grown in CDM at OD~600~ = 0.8. The cultures were then centrifuged for 20 min at 2700 × g. The supernatants were then filtered using 0.22-μm filters, 30% (w/v) ammonium sulfate was added to the samples, and the pH of the mixtures was adjusted to 4.0. Next, 20 mL N-butanol was added to each sample. The samples were centrifuged for 10 min at 1350 xg and 4 °C. The interfacial precipitate was collected and resuspended in 1 mL of 20 mM Tris--HCl pH 7.2 \[[@CR23]\]. Finally the concentration protein was determined by Bradford method \[[@CR24]\].

2D-PAGE electrophoresis and Mass Spectrometry {#Sec6}
---------------------------------------------

The 2-DE procedure and in-gel protein digestion were performed as described previously \[[@CR9], [@CR10]\]. Approximately 300 μg of the protein extract from of each condition was dissolved in rehydration buffer (Urea 7 M, thiourea 2 M, CHAPS 2%, Tris--HCl 40 mM, bromophenol blue 0.002%, DTT 75 mM, IPG Buffer 1%). Samples were applied to 18 cm pH 3--10 N.L strips (GE Healthcare, Pittsburgh, USA). Isoelectric focusing (IEF) was performed using the apparatus IPGphor 2 (GE Healthcare) under the following voltages: 100 V 1 h, 500 V 2 h, 1000 V 2 h, 10,000 V 3 h, 10,000 V 6 h, 500 V 4 h. The IPG strips were placed on 12% acrylamide/bis acrylamide gels in an Ettan DaltSix II system (GE Healthcare). The gels were stained with Coomassie Blue G-250 staining solution, and 2-DE gels were scanned using an Image Scanner (GE Healthcare). The Image Master 2D Platinum 7 (GE Healthcare) software was used to analyze the generated images and all spots were matched and analyzed by gel-to-gel comparison. The quantification of the spots was calculated according percentage volume (% Vol) and spots with reproducible changes in abundance were considered to be differentially expressed. Protein spots were excised from the gels, and in-gel digestion was carried out using trypsin enzyme (Promega, Sequencing Grade Modified Trypsin, Madison, WI, USA). The peptides were then desalted and concentrated using ZIP TIP C18 tips (Eppendorf).

The samples were subsequently analyzed for MS and MS/MS modes, using an MALDI-TOF/TOF mass spectrometer Autoflex IIITM (Bruker Daltonics, Billerica USA). The equipment was controlled in a positive/reflector way using the Flex-ControlTM software (Brucker Daltonics). External calibration was performed using peptide standards samples (angiotensin II, angiotensin I, substance P, bombesin, ACTH clip 1--17, ACTH clip 18--39, somatostatin 28, bradykinin Fragment 1--7, Renin Substrate tetra decapeptide porcine) (Bruker Daltonics). The peptides were added to the alpha-cyano-4-hydroxycinnamic acid matrix, applied on an Anchor-ChipTM 600 plate (Brucker Daltonics) and analyzed by Autoflex III. The search parameters were as follows: enzyme; trypsin; fixed modification, carbamidomethylation (Cys); variable modifications, oxidation (Met); mass values, monoisotopic; maximum missed cleavages, 1; and peptide mass tolerance of 0.005% Da (50 ppm). The results obtained by MS/MS were used to identify proteins utilizing the MASCOT\_ (<http://www.matrixscience.com>) program and compared with the genomic data of the Actinobacteria class deposited in the NCBI nr database.

2D nanoUPLC-HDMSE data acquisition and Data Processing {#Sec7}
------------------------------------------------------

The protein extracts from three biological replicates of each condition were concentrated using spin columns with a 10 kDa threshold (Millipore, Billerica, MA, USA) to perform the label-free proteomic analysis. The protein was denatured (0.1% *Rapi*GEST SF at 60 °C for 15 min) (Waters, Milford, CA, USA), reduced (10 mM DTT), alkylated (10 mM iodoacetamide) and enzymatically digested with trypsin (Promega). The digestion process was stopped by adding 10 μL of 5% TFA (Fluka, Buchs, Germany), and glycogen phosphorylase (Sigma, Aldrich, P00489) was added to the digested samples after digest at 20 fmol.uL^−1^ as an internal standard for normalization. Each replicate was injected using a two-dimensional reversed phase (2D RPxRP) nanoUPLC-MS (Nano Ultra Performance Liquid Chromatography Mass Spectrometry) approach with 171 multiplexed high definition mass spectrometry (HDMSE) label-free quantitation \[[@CR25]\]. Qualitative and quantitative experiments were performed using both a 1 h reversed phase gradient from 7% to 40% (v/v) acetonitrile (0.1% v/v formic acid) at 500 nL.min^−1^ and a nanoACQUITY UPLC 2D RPxRP Technology system \[[@CR26]\]. A nanoACQUITY 174 UPLC HSS T3 1.8 μm, 75 μm × 15 cm column (pH 3) was used with an RP XBridge BEH130 C18 5 μm 300 μm x 50 mm nanoflow column (pH 10). Typical on-column sample loads were 250 ng of the total protein digests for each of the 5 fractions (250 ng/fraction/load). All analyses were performed using nano electrospray ionization in the positive ion mode nanoESI (+) and a NanoLockSpray (Waters, Manchester, UK) ionization source. The mass spectrometer was calibrated using an MS/MS spectrum of \[Glu1\]-Fibrinopeptide B human (Glu-Fib) solution (100 fmol.uL-1) delivered through the NanoLockSpray source reference sprayer. Multiplexed data-independent (DIA) scanning with additional specificity and selectivity for non-linear 'T-wave' ion mobility (HDMSE) experiments were performed using a Synapt G2-S HDMS mass spectrometer (Waters, Manchester, UK).

Following the identification of proteins, the quantitative data were packaged using dedicated algorithms \[[@CR27]\] and searching against a database with default parameters to account for ions \[[@CR28]\]. The databases used were reversed on-the-fly during the database queries and appended to the original database to assess the false positive rate during identification. For proper spectra processing and database searching conditions, the ProteinLynxGlobalServer v.2.5.2 (PLGS) with IdentityE and ExpressionE informatics v.2.5.2 (Waters, Manchester, UK) was used. UniProtKB (release 2013_01) with manually reviewed annotations was used, and the search conditions were based on taxonomy (*Corynebacterium pseudotuberculosis*). One missed cleavage by trypsin was allowed be up to 1 and various modifications as carbamidomethyl (C), Acetyl N terminal, phosphoryl (STY) and oxidation (M) were allowed \[[@CR29]\]. The proteins collected were organized by the PLGS ExpressionE tool algorithm into a statistically significant list that corresponded to higher or lower regulation ratios between the different groups. For protein quantitation, we used the PLGS v2.5.2 software with the IdentifyE algorithm using the Hi3 methodology. The search threshold to accept each spectrum was the default value for a false discovery rate 4%. The quantitation values were averaged over all samples, and the standard deviations of *p* \< 0.05, which were determined using the ExpressionE software, refer to the differences between biological replicates.

Bioinformatic analysis {#Sec8}
----------------------

The proteins identified in 1002\_*ovis* under both conditions were analyzed using the following prediction tools: SecretomeP 2.0 server, to predict proteins exported from non-classical systems (positive prediction score greater than to 0.5) \[[@CR30]\] and PIPs software, to predict proteins in the pathogenicity islands \[[@CR31]\]. Gene ontology (GO) functional annotations were generated using the Blast2GO tool \[[@CR32]\].

Results {#Sec9}
=======

The main objective of this study was to assay the virulence of 1002\_*ovis* in a murine model after passage through mice. We thus carried out an in vivo survival assay using BALB/c mice infected with bacteria that did not contact with murine model (Ct) and bacteria recovered (Rc) from mice spleens. In this assay using an infection inoculum of 10^6^ CFU, all the animals infected with Rc died within 48 h after infection (Fig. [1a](#Fig1){ref-type="fig"}). On the other hand, the control group, infected with Ct*,* survived the evaluation period (6 days). Similarly, in an assay with a lower infective dose (10^5^ CFU), a 100% mortality was observed four weeks post infection with the recovered bacteria (Fig. [1b](#Fig1){ref-type="fig"}). Comparison of the Ct and Rc numbers isolated from the spleen within five days of infection (Fig. [1c](#Fig1){ref-type="fig"}) showed that the serial passage process affected the potential for spleen colonization during the infection. After four weeks of infection in the assay with 10^5^ CFU, bacteria were isolated from the spleen, liver, left and right kidney, only in mice infected with Rc (Fig. [1d](#Fig1){ref-type="fig"}). Finally, regarding the clinical signs, in the assay using 10^5^ CFU, caseous lesions were detected in different organs (liver, left kidney and right kidney) of all the animals infected only with Rc (data not shown). Altogether, these results showed that the serial passage process in a murine model increased the virulence potential of strain 1002\_*ovis*. In addition, these results confirmed the low virulence of this strain, which was previously suggested based on the composition of its extracellular proteome \[[@CR8]--[@CR10]\].Fig. 1Survival of Balb/C mice infected with strain 1002\_*ovis*. **a** The survival rate was measured to determine the virulence profile of strain 1002*\_ovis* control and recovered in mice infected with 10^6^ CFU of bacteria Ct = control condition, Rc recovered condition. **b** Survival rates of mice infected with 10^5^ CFU of Ct and Rc. **c** CFU in the spleen of BALB/c mice infected with control and recovered condition for the first five days of infection. **d** CFU in the different organs (spleen, left kidney, right kidney and liver) of BALB/c mice infected with control and recovered condition after four weeks of infection. The mortality rates were measured daily. Results represent three independent experiments. *P* values of \<0.05 were considered to be statistically significant, and asterisks indicate statistically significant differences

After passage in BALB/c mice, a dramatic change in the virulence potential of strain 1002*\_ovis* was observed. We thus hypothesized that this phenotypic change was visible at the proteome level since *C. pseudotuberculosis* virulence relies on the production of a proteinaceous virulence factor. Thus, considering the importance of extracellular proteins for bacterial virulence, the proteomic analysis was conducted on the extracellular proteomes of 1002*\_ovis* recovered from infected mice spleens in comparison to the control condition, using two proteomics approaches: 2-DE and 2D nanoUPLC-HDMS^E^. The electrophoretic resolution of the extracellular protein extract of Ct and Rc condition allowed the visualization of spots distributed over pH 3--10 (Fig. [2](#Fig2){ref-type="fig"}). A total of 14 spots were found to be differentially expressed between Ct and Rc condition, these spots were excised out of the gel, and identified by MS/MS (Table [1](#Tab1){ref-type="table"}). In the LC/MS analysis, we used the label-free quantitative proteomic to evaluate the relative difference between the proteome of Rc and Ct condition. In this analysis, only proteins which presented *p* \< 0.05 and differential expression (log2 ratios) equal or greater than a factor of 1.2 were considered, as described previously \[[@CR33]\]. We detected a total of 118 expressed differentially proteins, between Ct and Rc condition (Fig. [3](#Fig3){ref-type="fig"}) (Table [2](#Tab2){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}). Also, 48 proteins were assigned only to Ct (Additional file [2](#MOESM2){ref-type="media"}) and 32 proteins were exclusive to Rc (Table [3](#Tab3){ref-type="table"}) The information about sequence coverage and a number of identified peptides for each protein sequence identified, as well as the information about the native peptide are available at Additional file [3](#MOESM3){ref-type="media"}: Table S3.Fig. 2Two-dimensional electrophoresis of the extracellular proteins 1002\_*ovis* after following passage process: **a** Control condition. **b** Recovered condition. Red circle: spot proteins identified by MS/MS Table 1List of proteins identified in 1002\_*ovis* control and recovered by 2D-PAGE-MS/MSSpotDescriptionAccessionMW(kDa)/p.IPeptides NumberMascot ScoreMolecular function5, 6, 7Hypothetical proteinADL2003224.30/9.242189Unknown function11,29Trypsin-like serine proteaseADL2065325.72/6.49296Serine-type endopeptidase activity15Hypothetical proteinADL2171442.04/5.224159Catalytic activity20,34Corynomycolyl transferaseADL2161041.80/7.05258Transferase activity16Cytochrome c oxidase sub IIADL2130240.33/6.03296Cytochrome-c oxidase activity21Hypothetical proteinADL2191412.30/5.04253Unknown function12Hypothetical proteinADL1992219.86/4.302145Calcium ion binding8Hypothetical proteinADL0962624.30/9.243228Unknown27Hypothetical proteinADL2050831.62/9.52266Unknown22Phospholipase DADL1993534.09/8.914286Sphingomyelin phosphodiesterase D activity3EnolaseADL2060545.17/4.683271Phosphopyruvate hydratase activity17Trehalose corynomycolyl transferase BADL2181436.67/6.905245Transferase activity, transferring acyl groups other than24Hypothetical proteinADL2171440.90/5.053190Catalytic activity Fig. 3Volcano Plot show Log(2) Fold Change of the differentially expressed proteins detected by label-free proteomics between the recovered and control condition. Green: Up-regulated proteins; Grey: unchanged proteins; Red: Down-regulated proteins Table 2Proteins differentially produced among the recovered and control conditionAccessionDescriptionScoreFold Change_Log~(2)~ ^a^SecretomeP Transport  D9Q5H9_CORP1Periplasmic binding protein LacI5601,783,260.612642  D9Q6G4_CORP1Oligopeptide binding protein oppA^b^4120,13,000.892226  D9Q4T5_CORP1ABC transporter domain containing ATP1264,052,570.084974  D9Q7K5_CORP1Oligopeptide binding protein oppA^b^33697,172,110.873687  D9Q5B8_CORP1Oligopeptide binding protein oppA^b^852,881,880.849217  D9Q6C3_CORP1ABC type metal ion transport system permease650,431,590.078043  D9Q796_CORP1Glutamate binding protein GluB6254,68−1,460.840325  D9Q7W9_CORP1Iron(3+)-hydroxamate-binding protein fhuD2774,62−1,620.824030 Cell division  D9Q7G1_CORP1Septum formation initiator protein2071,461,380.551153 Cell adhesion  D9Q5H7_CORP1Hypothetical protein115906,31,510.840443 DNA synthesis and repair  D9Q7J1_CORP1GTP binding protein YchF3487,982,680.042575  D9Q5F7_CORP1Chromosome partitioning protein ParB^b^2467,242,440.052395  D9Q5G6_CORP1DNA polymerase III subunit beta1907,741,800.071008  D9Q5V6_CORP1Nucleoid associated protein^c^68097,591,590.070074 Transcription  D9Q6J8_CORP1DNA directed RNA polymerase subunit29671,461,380.094910  D9Q748_CORP1tRNA rRNA methyltransferase2467,241,270.060356  D9Q8L3_CORP1DNA directed RNA polymerase subunit omega3784,13−1,210.700214  D9Q6D1_CORP1DNA directed RNA polymerase subunit beta2611,89−1,270.067182  D9Q8A5_CORP1RNA polymerase-binding protein RbpA10787,51−1,750.103548 Translation  D9Q584_CORP130S ribosomal protein S620750,744,820.047667  D9Q6E4_CORP1Elongation factor G^b^16882,713,250.082321  D9Q5I3_CORP1Peptidyl prolyl cis trans isomerase^b^61648,392,910.142641  D9Q835_CORP1Phenylalanine tRNA ligase beta subunit1269,72,740.064869  D9Q6L0_CORP150S ribosomal protein L135689,372,640.101816  D9Q6H2_CORP150S ribosomal protein L5^b^3269,322,120.076250  D9Q918_CORP1Proline tRNA ligase^b^932,792,120.072151  D9Q6C0_CORP150S ribosomal protein L10^b^27143,511,860.031374  D9Q6F6_CORP150S ribosomal protein L23^b^6947,791,850.060878  D9Q6H1_CORP150S ribosomal protein L2427887,331,750.078408  F9Y2W9_CORP1Hypothetical protein3152,391,750.591013  D9Q6H6_CORP130S ribosomal protein S8^c,b^4941,191,560.088407  D9Q6F3_CORP130S ribosomal protein S10^b^25117,551,540.048124  D9Q6G2_CORP150S ribosomal protein L292467,241,440.050948  D9Q401_CORP150S ribosomal protein L27^b^2467,241,380.081399  D9Q7E8_CORP150S ribosomal protein L251358,05−1,280.037225  D9Q6H8_CORP150S ribosomal protein L188920,94−1,310.049024  D9Q7S4_CORP1Homoserine dehydrogenase698,17−1,400.035138  D9Q6B7_CORP150S ribosomal protein L110218.08−1,630.633387  D9Q4T4_CORP1ATP dependent chaperone protein ClpB1883,16−1,800.045308  D9Q8N9_CORP1Aspartate tRNA ligase1004,33−2,180.092415  D9Q7S2_CORP1Arginine tRNA ligase2679,11−2,440.051908 Pathogenesis  D9Q8M7_CORP1Metallopeptidase family M243213,835,550.050024  D9Q608_CORP1Penicillin binding protein transpeptidase^b^1215,323,680.859830  D9Q827_CORP1Metallo beta lactamase superfamily protein^c^629,382,640.144158  D9Q721_CORP1Hypothetical protein^c^1120252,240.260801  D9Q7K8_CORP1Trypsin like serine protease35041,271,960.648370  D9Q416_CORP1ATP dependent Clp protease proteolytic^b^2467,241,770.087255  D9Q639_CORP1Secreted hydrolase^b^22798,131,750.072385  D9Q588_CORP1Penicillin binding protein^b^9951,611,260.916125 Energy metabolism  D9Q787_CORP1Glucose-6-phosphate isomerase1025,894,500.058841  D9Q7G0_CORP1Enolase^b^53290,952,180.068928  D9Q651_CORP1Succinate dehydrogenase flavoprotein797,482,020.159059  D9Q4P2_CORP1Acetate kinase^b^10828,791,960.063340  D9Q8G5_CORP1Aconitate hydratase^b^4250,811,850.217637  D9Q4Z7_CORP1Phosphoenolpyruvate carboxykinase GTP^b^8764,351,660.147167  D9Q7X0_CORP16 phosphofructokinase1806,651,600.052885  D9Q648_CORP1Dihydrolipoyl dehydrogenase4110,081,570.047180  D9Q7T8_CORP1ATP synthase subunit alpha2467,241,490.070875  D9Q752_CORP1Citrate synthase6299,21−1,210.116042  D9Q895_CORP16-Phosphogluconate dehydrogenase4246,26−1,890.050906 Lipid metabolism  D9Q520_CORP1Glycerophosphoryl diester phosphodieste^c^2494,254,030.802154  D9Q718_CORP1Methylmalonyl CoA carboxyltransferase 1^b^2467,242,160.049504 Amino acid metabolism  D9Q5X8_CORP1Aspartokinase^b^1944,812,860.043575  D9Q4C2_CORP1Succinyl CoA Coenzyme A transferase10894,631,630.061344  D9Q3L8_CORP1Glutamine synthetase320,71−1,230.263700  D9Q8H7_CORP1Cysteine desulfurase1689,36−1,700.067087 Stress response  D9Q929_CORP1Mycothione glutathione reductase490,362,670.085017  D9Q5T5_CORP1Glyoxalase Bleomycin resistance protein^c^8420,322,210.226764  D9Q424_CORP1DSBA oxidoreductase12179,82,090.061566  D9Q566_CORP1Universal stress protein A^b^2498,691,700.034684  D9Q4P4_CORP1Ferredoxin ferredoxin NADP reductase^b^1086,711,690.083585  D9Q824_CORP1Stress related protein^b^2467,241,540.035291  D9Q692_CORP1Thiol disulfide isomerase thioredoxin3721,88−2,250.438415 Metabolism of nucleotides and nucleic acids  D9Q4Y6_CORP1Deoxycytidine triphosphate deaminase887,262,390.216897  D9Q6J1_CORP1Adenylate kinase15629,862,210.059568  D9Q8L4_CORP1Guanylate kinase2467,241,340.050095  D9Q6T2_CORP1Ribokinase890,09−1,230.032324  D9Q4E9_CORP1Adenylosuccinate lyase1441,99−1,540.035597  D9Q6P0_CORP1D methionine binding lipoprotein metQ11519,67−1,930.817217 Carbohydrate metabolism  D9Q8V2_CORP1UDP glucose 4 epimerase^b^2001,763,130.094403  D9Q6V6_CORP1Phosphomannomutase ManB1730,632,050.053146  D9Q659_CORP1Formate acetyltransferase5456,951,540.539548  D9Q423_CORP1Ribose-5-phosphate isomerase B2467,241,380.064467  D9Q6V1_CORP1Mannose-1-phosphate guanylyltransferase1612,45−1,210.068085 Nitrogen metabolism  D9Q4Q8_CORP1Cytochrome c nitrate reductase small1118,332,680.901856 Unknow function  D9Q6T0_CORP1Hypothetical protein2277,63,620.050552  D9Q4R2_CORP1Hypothetical protein442,073,350.866986  D9Q6N1_CORP1Hypothetical protein561,843,020.062141  D9Q8Q4_CORP1Hypothetical protein^c^72711,52,960.974016  D9Q832_CORP1Hypothetical protein1774,592,900.752478  D9Q3S8_CORP1Hypothetical protein^d^837,62,780.231421  D9Q7M9_CORP1Hypothetical protein3246,282,600.147602  D9Q7I6_CORP1Hypothetical protein3751,962,420.707595  D9Q739_CORP1Hypothetical protein2845,772,280.836229  D9Q4C5_CORP1Hypothetical protein1339,31,830.023133  D9Q5C3_CORP1Hypothetical protein111234,61,490.946918  D9Q700_CORP1Hypothetical protein2467,241,490.072810  D9Q657_CORP1Hypothetical protein1172,661,410.830926  D9Q6F2_CORP1Hypothetical protein2467,241,340.061860  D9Q7X5_CORP1Hypothetical protein38716,45−1,210.825761  D9Q4T9_CORP1Hypothetical protein553,76−1,280.934591  D9Q6R6_CORP1Hypothetical protein1457,62−1,400.206908  D9Q890_CORP1Hypothetical protein1948,52−1,510.847549  D9Q6M6_CORP1Hypothetical protein^c^1935,68−1,900.823541 Others  D9Q6I3_CORP1Maltotriose binding protein5210,95,220.864851  D9Q4A3_CORP1DsbG protein3101,132,060.814366  D9Q6N9_CORP1D methionine binding lipoprotein metQ2665,581,790.764416  D9Q732_CORP1Carbonic anhydrase^b^689,151,660.130559  D9Q6W6_CORP1Lipoprotein LpqB1484,311,630.670057  D9Q556_CORP1LSR2 like protein2714,211,490.096802  D9Q5Q0_CORP1UPF0145 protein2467,241,370.025009  D9Q7W0_CORP1Hypothetical protein2467,241,260.039678  D9Q701_CORP1UPF0182 protein1682,981,260.869411  D9Q8A3_CORP1Protein yceI^b^16885,011,210.901679  D9Q5X4_CORP1Serine aspartate repeat containing protein528,36−1,820.892317  D9Q826_CORP1DoxX family protein697,26−2,080.614317  D9Q7W3_CORP1Mycothiol acetyltransferase947,33−2,110.214833  D9Q407_CORP1Ornithine cyclodeaminase2566,18−2,580.048247^a^Fold change - Ratio values to: 1002Rc:11002Ct_Log(2)Ratio ≥ 1.2 proteins with *p* \< 0.05^b^Identified in an isolated of *C. pseudotuberculosis* from ovine lymph nodes \[Rees et al. \[[@CR12]\]^c^Induced in 1002\_*ovis* during to stress nitrosative \[Pacheco et al. \[[@CR57]\], Silva et al. \[[@CR58]\]^d^Predicted LPXTG cell wall-anchoring motif Table 3List of proteins identified in the exclusive proteome of recovered-conditionAccessionDescriptionScoreBiological processSecretomePD9Q869_CORP1Esterase^a^251.44Others0.862935D9Q575_CORP1Cation transport protein1961.29Transport0.062276D9Q5N5_CORP1Uncharacterized iron regulated membrane^a^46.77Transport0.855681D9Q3T9_CORP1Pyridoxamine kinase216.2Cofactor metabolism0.083313D9Q751_CORP1Phosphoserine aminotransferase639.64Amino acid metabolism0.151778D9Q537_CORP1LytR family transcriptional regulator^a^375.8Transcription0.766483D9Q7F2_CORP1Multicopper oxidase74.63Stress response0.278840D9Q525_CORP1ABC transporter substrate binding lipoprotein283.38Transport0.452814D9Q6P2_CORP1Manganese ABC transporter substrate binding^a^236.6Transport0.774461D9Q4C8_CORP1Phosphate ABC transporter phosphate binding^a^125.4Transport0.840195D9Q4L0_CORP1D alanyl D alanine carboxypeptidase OS426.74Others0.232261D9Q4T7_CORP1Hyphotetical protein157.52Unknow function0.349026D9Q5A9_CORP1Hyphotetical protein218.02Unknow function0.907333D9Q476_CORP1Hyphotetical protein510.32Unknow function0.066368D9Q5B3_CORP1Glucosamine-6-phosphate deaminase^b^524,55Carbohydrate metabolism0.079507D9Q474_CORP1Glutamate racemase343,98Cell wall organization0.040278D9Q7N5_CORP1O-methyltransferase619,11DNA process0.032455D9Q5N3_CORP1Gamma type carbonic anhydratase577,75Others0.035357D9Q4X0_CORP1Urease accessory protein UreD333,12Others0.055896D9Q5J0_CORP1Phospholipase D^b^40,25Pathogenesis0.409585D9Q8S8_CORP1Copper resistance protein CopC4315,26Stress response0.964015D9Q493_CORP1Glutaredoxin like protein nrdH725,98Stress response0.033036D9Q6Y6_CORP1ATP dependent RNA helicase rhlE1438,25Transcription0.060627D9Q4M0_CORP1Cell wall channel4008,59Transport0.025882D9Q4V1_CORP1CP40558,79Pathogenesis0.926013D9Q6V9_CORP1Hyphotetical protein1278,45Unknow function0.953803D9Q6A8_CORP1Hyphotetical protein326,47Unknow function0.918886D9Q485_CORP1Hyphotetical protein2795,11Unknow function0.890081D9Q4N2_CORP1Hypothetical protein^a^708,75Unknow function0.857050D9Q559_CORP1Hypothetical protein^a^475,62Unknow function0.472378D9Q4L8_CORP1Hyphotetical protein5324,08Unknow function0.038893D9Q4T0_CORP1Hyphotetical protein732,37Unknow function0.037132^a^Induced in 1002_ovis during to stress nitrosative \[Pacheco et al. \[[@CR57]\], Silva et al. \[[@CR58]\]^b^Identified in an isolated of *C. pseudotuberculosis* from ovine lymph nodes \[Rees et al. \[[@CR12]\]

The proteins identified in both conditions were analyzed by SecretomeP \[[@CR29]\] to assess whether these proteins could be exported by non-classical secretion systems. Among the expressed differentially proteins 31% (37 proteins) were predicted as secreted through non-classical secretion systems. In turn, when analyzed the exclusive proteome of each condition 19% (6 proteins) and 27% (13 proteins) were considered to be exported by non-classical secretion systems for recovered and control condition, respectively. The PIPS tool was used to evaluate whether the genes that encode the proteins which were differentially expressed and identified in the exclusive proteome of the Rc condition are included in predicted pathogenicity islands. According these analysis 16 proteins was encoded by genes located on a predicted pathogenicity island; these proteins are related to cellular metabolism, pathogenesis, transport pathway, stress response and unknown function (Additional file [4](#MOESM4){ref-type="media"}). To classify the proteins identified in functional groups, we used the Blast2Go tool \[[@CR31]\]; according to this analysis, the proteins were grouped into 17 biological processes (Fig. [4](#Fig4){ref-type="fig"}). Among these proteins, we identified processes that are directly involved in bacterial virulence, such as protein transport, pathogenesis, cell adhesion and stress response (Table [2](#Tab2){ref-type="table"}).Fig. 4Biological processes differentially regulated in 1002\_*ovis* after passage in mice. Analysis of the differentially expressed proteins grouped into biological processes for strain 1002\_*ovis* after passage in mice

Important factors directly linked to *C. pseudotuberculosis* virulence, like the PLD phospholipase, as well as, the CP40 protease were detected only in the proteome of recovered 1002\_*ovis* (Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}). Also, components of several secretion systems were also activated in the bacteria recovered. These include proteins related to hemin uptake, ATP-binding cassette (ABC) transporters and the Opp transporter, like OppA, OppC, and OppD. Proteins related to detoxification process were also specifically identified in the Rc supernatant: e.g. the glutaredoxin-like protein NrdH, which belongs to the NrdH-redoxins, a family of small protein disulfide oxidoreductases \[[@CR34]\], mycothiol glutathione reductase present in Actinobacteria \[[@CR35]\] and copper resistance protein CopC (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). In addition, we have identified 31 proteins in the recovered condition that also were detected in a strain of *C. pseudotuberculosis* isolated directly from ovine lymph nodes \[[@CR12]\] (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). Proteins involved in the resistance to antimicrobial agents, such as penicillin-binding proteins, metallo-beta-lactamase, and penicillin-binding protein transpeptidase and proteases like Clp protease involved in the expression of cytotoxins in *Staphylococcus aureus* and *Listeria monocytogenes* \[[@CR36], [@CR37]\] were found induced in Rc supernatant.

Discussion {#Sec10}
==========

To investigate the protein factors that could influence the adaptive processes of *C. pseudotuberculosis* biovar *ovis* during the infection process, we combined a unique bacterial passage experiment in mice with proteomic analyses of 1002*\_ovis* culture supernatants, collected before and after passage. In the first analysis, we observed that strain 1002*\_ovis* (isolated from caprine) exhibited a low virulence potential, which is consistent with previous reports indicating the low virulence potential of this strain \[[@CR38], [@CR39]\]. Although a recent in silico analysis of the 1002\_*ovis* genome predicted various genes involved in virulence \[[@CR40]\], studies examining the exoproteome of this strain under laboratory growth conditions failed to detect many of these virulence proteins (e.g., PLD exotoxin or proteins involved in the pathway of cell invasion, detoxification) \[[@CR8]--[@CR10]\].

One explanation for this relies on the fact that after being first isolated, strains 1002\_*ovis* have been maintained, in vitro, under laboratory conditions with extensive passages on the culture medium, which may alter the gene expression profile of the strain, especially for effectors related to bacterial virulence. This phenomenon has also been reported in other pathogens such as *Mycobacterium bovis*, *Helicobacter pylori*, *S. aureus*, and *L. monocytogenes*. In vitro passages of these bacteria on culture medium altered both bacterial physiology and virulence profile \[[@CR41]--[@CR44]\]. However, we showed that the bacterial passage process in a murine model changed the virulence potential of strain 1002*\_ovis*. Previous reports on experimental serial passages showed that pathogens such as *H. pylori*, *Escherichia coli, Xenorhabdus nematophila*, *Arcobacter butzleri*, and *Salmonella enterica* also exhibited altered virulence profiles after in vivo passage in a host, which helped identifying factors that contribute to infectious process \[[@CR14]--[@CR19]\]. Thus, as observed in these pathogens, the recovered condition also showed increased capacity to persist into host, when compared with control condition. The altered physiology and virulence status observed in 1002*\_ovis* is supported by our proteomic analyses, where several proteins involved in processes favoring infection and host adaptation were differentially expressed after passage in mice.

Although our study focused on the *C. pseudotuberculosis* extracellular proteins, cytoplasmic proteins were also detected in the proteomic analyses. The presence of cytoplasmic proteins in the extracellular fraction is reported in several other proteomic studies \[[@CR8]--[@CR10], [@CR12], [@CR45]\]. It may be partially due to cell lysis and thus, be considered artifacts. However, cytoplasmic proteins in the culture supernatant may act as *moonlighting* proteins and be exported via a non-classical secretion pathway \[[@CR30], [@CR46]\]. The *moonlighting* proteins are described both Gram-positive and Gram-negative bacteria, and can be detected in different subcellular locations (cytoplasm, membrane, cell surface, and extracellular environment) and exhibit distinct functional behavior depending on the host cell type \[[@CR46], [@CR47]\]. Interestingly, some proteins, such as Chromosome partitioning protein ParB, Phosphoenolpyruvate carboxykinase GTP, Methylmalonyl CoA carboxyltransferase 12S subunit, Acetate kinase, and Enolase, induced in the Rc supernatants were identified only in the membrane shaving of *C. pseudotuberculosis* harvested directly from ovine lymph nodes \[[@CR12]\].

The passage process in mice was also able to induce other proteins identified in Rc supernatants, and which contribute to the adhesion process. Proteins with an LPTXG domain, which characterizes the cell-wall anchored proteins, were identified and included monomers of membrane pilus. This latter class of proteins is described in pathogenic *Corynebacterium* species and may contribute especially in the process of cellular adhesion \[[@CR48]\]. In *Campylobacter jejuni,* serial passages in mice induce the expression of invasiveness and increase the capacity of cell invasion \[[@CR13]\]. Components of the Opp system were induced by the passage process, too. The Opp system facilitates the uptake of extracellular peptides, which are further used as carbon and nitrogen sources for bacterial nutrition \[[@CR49]\]. Proteins that comprise the Opp system also were induced in a field isolated of *C. pseudotuberculosis* biovar *ovis*, when compared with the strain C231\_*ovis* a laboratory reference strain \[[@CR12], [@CR50]\]. In the pathogen *Mycobacterium avium* the *OppA* gene was highly expressed during the infection in a mouse model \[[@CR51]\]. We have identified known secreted virulence factors as CP40 serine protease, which previously shown to be necessary for *C. pseudotuberculosis* virulence potential and to induce an immune response \[[@CR52], [@CR53]\].

An important factor that precedes the chronic stage of infection by *C. pseudotuberculosis* is the capacity of this pathogen to disseminate within the host, which consequently favors the establishment of the disease \[[@CR3]\]. In *C. pseudotuberculosis*, this process is mediated by the action of PLD exotoxin, a major virulence factor of this pathogen \[[@CR54], [@CR55]\] that catalyzes the dissociation of sphingomyelin and increases vascular permeability, which contributes to the dissemination process of *C. pseudotuberculosis* in the host. Here, PLD was only detected in the proteome of the Rc condition. This result is noteworthy because, a previous proteomic study performed by our research group, PLD was not identified in the extracellular proteome of 1002*\_ovis* \[[@CR8]--[@CR10]\]. McKean *et al*. \[[@CR5]\] showed that *pld* expression is expressed by different environmental factors, thus during the infection and recuperation process 1002\_*ovis* was exposed to different environmental and stimulus, which may have affected the *pld* expression. A study showed that a *pld* mutant strain is indeed unable to disseminate and yields reduced virulence \[[@CR55]\]. Here, we observed the presence of caseous lesions in different organs only at the end of experimental infection, only in the group of mice infected with the Rc condition. Altogether, the observations suggest that the expression of PLD can be modified by the passage in the host and can thus change the virulence potential of 1002\_*ovis*.

Another attribute of PLD is its capacity to alter the viability of macrophage cells during the infection \[[@CR5]\]. However, before promoting macrophages lysis, *C. pseudotuberculosis* has to be able to resist the hostile environment inside macrophages mainly against reactive oxygen species (ROS) and reactive nitrogen species (RNS). Thus, the induction of proteins involved in detoxification processes in Rc could be contributed for its resistance against ROS and RNS. The inductions of proteins related to oxidative stress also were observed in *Shigella flexneri*, after recuperation process in an in vivo infection model. We detected the mycothione glutathione reductase, a component of the mycothiol system, which is present in *Mycobacterium and Rhodococcus* genera. This system is used as an alternative mechanism of disulphide reduction and contributes to the cytosolic redox homeostasis and the resistance to ROS \[[@CR35]\]. Glutaredoxin-like protein, NrdH, which plays an important role in the resistance to ROS, and is present in *C. glutamicum* \[[@CR34]\] and *M. tuberculosis* \[[@CR56]\] was also detected.

On the other hand, some proteins like dihydroxybiphenyl dioxygenase, Metallo beta lactamase superfamily protein, Formamidopyrimidine DNA glycosylase, MerR family transcriptional regulator, which were induced by 1002\_*ovis* during the exposition to nitric oxide \[[@CR57], [@CR58]\] were also found induced in this study in the recovered condition. These proteins are related to different processes of resistance to nitrosative stress, DNA repair, antibiotic resistance, and transcription, these results show a set of proteins involved in the adaptation process of 1002\_*ovis* to nitric oxide, which could contribute to the pathogenic process of this pathogen. Another type of defense of the host immune system against bacterial infection is the utilization of copper \[[@CR59]\]. Here, CopC, a protein related to copper resistance, was detected in recovered 1002\_*ovis*. In *M. tuberculosis,* proteins involved in copper resistance are essential to virulence \[[@CR60], [@CR61]\]. Thus, the association of this factor related to an antioxidant system with PLD could promote an effective pathway of defense against the action of the innate immune system and consequently contributes to virulence process of *C. pseudotuberculosis*.

Conclusion {#Sec11}
==========

In conclusion, the virulence potential and proteomic profiles of strain 1002*\_ovis* undergo dramatic changes after recovery from experimentally infected mice. The proteomic screening outlined, after the serial passage in murine model showed a set of proteins that were induced in the recovered condition. Into this group were detected known secreted virulence factors, as well as some proteins which could contribute in its virulence. Therefore, more study is necessary to show the true role of these proteins in the virulence of *C. pseudotuberculosis*. Altogether, our results demonstrate that in vitro passages alter the expression of *C. pseudotuberculosis* exoproteome leading to a reduced virulence and that a single passage in vivo, in a murine model, can induce significant changes in the *C. pseudotuberculosis* extracellular proteome, contributing to the increase in virulence of this pathogen.
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